Regence Logos
Medical Policy

Laboratory Section

Policy Name Date Modified
Allergy and Sensitivity Tests of Uncertain Efficacy 09/01/2019
Analysis of Proteomic and Metabolomic Patterns for Early Detection or Assessing Risk of Cancer 04/01/2020
Biochemical Markers of Alzheimer's Disease 01/01/2020
Bone Turnover Markers for Diagnosis and Management of Osteoporosis and Diseases Associated with High Bone Turnover 09/01/2019

Circulating Tumor DNA and Circulating Tumor Cells for Management (Liquid Biopsy) of Solid Tumor Cancers

COVID-19 Antibody Testing 05/20/2020
In Vitro Chemoresistance and Chemosensitivity Assays 01/01/2020
Laboratory and Genetic Testing for Use of 5-Flurouracil  (5-FU) in Patients with Cancer 03/01/2020
Laboratory and Genetic Testing for use of Thiopurines 05/01/2020
Laboratory Tests for Heart and Kidney Transplant Rejection 10/01/2019
Measurement of Lipoprotein-Associated Phospholipase A2 Lp-PLA2) in the Assessment of Cardiovascular Risk 07/01/2019
Measurement of Serum Antibodies to Infliximab, Adalimumab, Ustekinumab, and Vedolizumab 10/01/2019
Molecular Testing in the Management of Pulmonary Nodules 10/01/2019
Multi-biomarker Disease Activity Blood Test for Rheumatoid Arthritis 08/01/2019
Multianalyte Assays with Algorithmic Analyses for the Evaluation and Monitoring of Patients with Chronic Liver Disease 04/01/2020
Multimarker and Proteomics-based Serum Testing Related to Ovarian Cancer 03/01/2020
Placental Rapid Immunoassay for Detection of Fetal Membrane Rupture 04/01/2020
Protein Biomarkers for Screening, Detection, and/or Management of Prostate Cancer 02/01/2020
Salivary Hormone Testing for Aging and Menopause 04/01/2020
Serum Holotranscobalamin as a Marker of Vitamin B12 (i.e., Cobalamin) Status 04/01/2020
Urinary Biomarkers for Cancer Screening, Diagnosis, and Surveillance 10/01/2019

Urine Drug Testing for Substance Use and Pain Management


Vitamin D Testing